Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
Dallas, Texas–(Newsfile Corp. – June 4, 2025) – Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage biotechnology company based in Bellaire, Texas, pioneering RNA interference (RNAi) therapeutics through its proprietary DNAbilize® platform. This innovative technology employs neutral-charge, liposomal delivery of antisense oligonucleotides, enhancing drug stability and cellular uptake while minimizing toxicity. The Company’s lead candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in Phase 2 trials for acute myeloid leukemia (AML). A modified version, BP1001-A, is undergoing Phase 1/1b trials for solid tumors and has shown promise in preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, targets the Bcl-2 protein and is being evaluated for blood cancers and solid tumors. Bio-Path is also preparing an Investigational New Drug (IND) application for BP1003, a STAT3 inhibitor aimed at treating pancreatic cancer.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Phase 2 prexigebersen data shows potential for FDA approval in AML treatment.
- BP1001-A trial shows early signs of efficacy in advanced solid tumors.
- Advancing pipeline backed by strategic R&D and a robust patent portfolio.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254522
View more news from Reportable, Inc.
You are receiving this email because you have previously indicated your interest in receiving news for Reportable, Inc.
If you no longer want to receive messages from us, you can click here to unsubscribe.
Anti-Spam Policy | Privacy Policy
The post Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 first appeared on PressReleaseCC.
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 first appeared on Web and IT News.